Hengrui Medicine's (600276.SH) product receives orphan drug designation approval from the US FDA

Wisdom Financial APP News, Hengrui Medicine (600276.SH) announced that recently, the company's product Injection Rui Kang Qutuxuzumab combined with Adebiru monoclonal antibody injection and chemotherapy for the treatment of gastric cancer or gastroesophageal junction adenocarcinoma has been granted orphan drug qualification by the United States Food and Drug Administration (FDA). Orphan drugs, also known as rare disease drugs, refer to drugs used for the prevention, treatment, and diagnosis of rare diseases.